Axiom Investors LLC DE Acquires 853 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Axiom Investors LLC DE grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 10,040 shares of the biotechnology company's stock after purchasing an additional 853 shares during the quarter. Axiom Investors LLC DE's holdings in United Therapeutics were worth $3,543,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics during the fourth quarter worth about $25,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in United Therapeutics during the fourth quarter valued at approximately $131,000. Institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on UTHR. UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $388.25.

Remove Ads

Insider Buying and Selling at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $940,373.07. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,500 shares of company stock worth $26,134,500. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $4.90 during trading hours on Thursday, hitting $307.36. 431,930 shares of the company's stock traded hands, compared to its average volume of 450,164. United Therapeutics Co. has a twelve month low of $227.75 and a twelve month high of $417.82. The firm has a market cap of $13.80 billion, a P/E ratio of 13.50, a P/E/G ratio of 0.97 and a beta of 0.64. The stock's fifty day moving average price is $336.64 and its two-hundred day moving average price is $355.09.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the prior year, the company earned $4.36 EPS. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.